WuXi Biologics (Cayman) Inc.
2269
Rang in aandelen
#987
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman)... Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Aandeelprijs
$5.77
Marktkapitalisatie
$23.74B
Verandering (1 dag)
-8.38%
Verandering (1 jaar)
25.13%
Land
CN
Handel WuXi Biologics (Cayman) Inc. (2269)
Categorie
Healthcare
P/S-ratio voor WuXi Biologics (Cayman) Inc. (2269)
P/S-ratio op October 2026 TTM: 6.71
Volgens de meest recente financiële rapporten en aandelenkoers van WuXi Biologics (Cayman) Inc. is de huidige P/S-ratio (TTM) 6.71. Eind 2024 had het bedrijf een P/S-ratio van 3.60.
P/S-ratiohistoriek voor WuXi Biologics (Cayman) Inc. van 2014 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 6.71 | 23.99% |
| 2025 | 5.41 | 50.12% |
| 2024 | 3.60 | -43.29% |
| 2023 | 6.36 | -55.99% |
| 2022 | 14.44 | -55.19% |
| 2021 | 32.23 | -49.91% |
| 2020 | 64.36 | 118.36% |
| 2019 | 29.47 | 29.19% |
| 2018 | 22.81 | -6.32% |
| 2017 | 24.35 | -16.00% |
| 2016 | 28.99 | -39.77% |
| 2015 | 48.14 | -37.59% |
| 2014 | 77.13 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | 49.41% |
US
|
|
| 40.55 | 504.51% |
US
|
|
| 3.96 | -40.95% |
AU
|
|
| 10.15 | 51.26% |
NL
|
|
| - | - |
CH
|
